Oxygenta Pharmaceutical Ltd — Important, 23-05-2026: Company Update

Oxygenta Pharmaceutical's board approved the financial results for the quarter and year ended March 31, along with an unmodified audit opinion. The company reported a net loss of 1.70 Cr for the quarter and 17.57 Cr for the full year. Revenue from operations for the quarter stood at 49.61 Cr, rising to 112.98 Cr for the full year. The board strengthened its leadership by appointing Mr. Amireddy Venkatesu Reddy as an Executive Director and Mr. Janardhana Reddy Yeddula as an Independent Director, both subject to shareholder approval. These additions bring significant pharmaceutical operations and finance expertise.